Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/117511
Title: ANTIANDROGEN ICARITIN ACTS AS A MODULATOR OF ANDROGEN RECEPTOR TO INHIBIT PROSTATE CANCER GROWTH
Authors: TAN MEI HUI EILEEN
Keywords: Androgen Receptor, Drug, Icaritin, Prostate Cancer, Arylhydrocarbon Receptor, CRPC
Issue Date: 23-Jul-2014
Source: TAN MEI HUI EILEEN (2014-07-23). ANTIANDROGEN ICARITIN ACTS AS A MODULATOR OF ANDROGEN RECEPTOR TO INHIBIT PROSTATE CANCER GROWTH. ScholarBank@NUS Repository.
Abstract: ANDROGEN RECEPTORS (AR) AND ANDROGENS PLAY A PIVOTAL ROLE IN PROSTATE CANCER. INDEED, ANDROGEN BLOCKADE BY DRUGS THAT PREVENT THE PRODUCTION OF ANDROGENS AND/OR BLOCK THE ACTION OF THE AR INHIBITS PROSTATE CANCER GROWTH. HOWEVER, RESISTANCE TO THE ACTION OF THESE DRUGS OFTEN OCCURS AFTER 2-3 YEARS AS PATIENTS DEVELOP CASTRATION-RESISTANT PROSTATE CANCER (CRPC). IN CRPC, FUNCTIONAL AR REMAINS A KEY REGULATOR. HENCE, THERE IS A CONSTANT NEED FOR THE CONTINUOUS DEVELOPMENT AND DISCOVERY OF NEW DRUG LEADS THAT TARGETS ANDROGEN RECEPTOR FOR TREATMENT OF PROSTATE CANCER HERE, WE REPORT ON THE THERAPEUTIC POTENTIAL OF ICARITIN, A NATURAL PRENYLFLAVONOID, WHICH EFFECTIVELY TARGETS AR, INHIBITS GROWTH AND INDUCES CELL DEATH OF PROSTATE CANCER CELLS LNCAP, C4-2, CWR22RV1 AND VCAP. ICARITIN INHIBITED THE ACTION OF AR IN A DUAL FASHION, BY FIRSTLY DISRUPTING THE AR TRANSCRIPTIONAL ACTIVATION; AND SECONDLY BY INDUCING ARYL HYDROCARBON RECEPTOR-DEPENDENT PROTEASOMAL DEGRADATION OF AR. ICARITIN LED
URI: http://scholarbank.nus.edu.sg/handle/10635/117511
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
TanMHE.pdf20.86 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

128
checked on Jan 19, 2018

Download(s)

16
checked on Jan 19, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.